

1 **Evaluating the effect of COVID-19 on dispensing patterns: a**
2 **national cohort analysis**

3 Authorship list

4 Fatemeh Torabi*: Population Data Science and Health Data Research UK, Swansea University

5 Ashley Akbari*: Population Data Science and Health Data Research UK, Swansea University

6 Laura North: Population Data Science and Health Data Research UK, Swansea University

7 Daniel Harris: Population Data Science and Health Data Research UK, Swansea University

8 Gareth Davies: Population Data Science and Health Data Research UK, Swansea University

9 Mike Gravenor: Swansea University

10 Rowena Griffiths: Population Data Science and Health Data Research UK, Swansea University

11 Jane Lyons: Population Data Science and Health Data Research UK, Swansea University

12 Neil Jenkins: NHS Wales Shared Services Partnership

13 Andrew Morris: Swansea University

14 Julian Halcox: Population Data Science and Health Data Research UK, Swansea University

15 Ronan A. Lyons: Population Data Science and Health Data Research UK, Swansea University

16

17

18 * Lead Author(s)

19

20

21

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

22

23

24 **Abstract**

25 **Background**

26 Medication prescribing and dispensing often regarded as one of the most effective ways to
27 manage and improve population health. Prescribed and dispensed medications can be
28 monitored through data linkage for each patient. We hypothesised that changes in patient care
29 resulting from COVID-19, changed the way patients access their prescribed medication.

30 **Objective** To develop an efficient approach for evaluation of the impact of COVID-19 on drug
31 dispensing patterns.

32 **Methods**

33 Retrospective observational study using national patient-level dispensing records in Wales-
34 UK. Total dispensed drug items between 01-Jan-2016 and 31-Dec-2019 (counterfactual pre-
35 COVID-19) were compared to 2020 (COVID-19 year). We compared trends of dispensed items
36 in three main British National Formulary (BNF) sections(Cardiovascular system, Central
37 Nervous System, Immunological & Vaccine) using European Age-Standardized rates. We
38 developed an online tool to enable monitoring of changes in dispensing as the pandemic
39 evolves.

40 **Result**

41 Amongst all BNF chapters, 52,357,639 items were dispensed in 2020 compared to 49,747,141
42 items in 2019 demonstrating a relative increase of 5.25% in 2020(95%CI[5.21,5.29]).
43 Comparison of monthly patterns of 2020 and 2019 dispensed items showed a notable difference
44 between the total number of dispensed drug items each month, with an average difference (D)

45 of +290,055 and average Relative Change (RC) of +5.52%. The greatest RC was observed in
46 a substantial March-2020 increase (D=+1,501,242 and RC=+28%), followed by second peak
47 in June (D=+565,004, RC=+10.97%). May was characterised by lower dispensing (D=-
48 399,244, RC=-5.9%). Cardiovascular categories were characterised, across all age groups, by
49 dramatic March-2020 increases, at the epidemic peak, followed by months of lower than
50 expected dispensing, and gradual recovery by September. The Central Nervous System
51 category was similar, but with only a short decline in May, and quicker recovery. A stand-out
52 grouping was Immunological and Vaccine, which dropped to very low levels across all age
53 groups, and all months (including the March dispensing peak).

54 **Conclusions**

55 Aberration in clinical service delivery during COVID-19 led to substantial changes in
56 community pharmacy drug dispensing. This change may contribute to a long-term burden of
57 COVID-19, raising the importance of a comprehensive and timely monitoring of changes for
58 evaluation of the potential impact on clinical care and outcomes

59

60

61

62

63

64

65 **Introduction**

66 The novel coronavirus disease 2019 (COVID-19) pandemic has resulted in unprecedented
67 changes on health care services provision (1). While technology has provided an increase in
68 telephone or virtual appointments there has been an overall net reduction in primary care
69 appointments (2). Increase in demand for essential medicines coupled with complex medicines
70 supply chain issues, enforcement of social distancing, quarantine, and self-isolation has
71 impacted the prescribing and dispensing of medicines (3)(4).

72 Studies using survey and patient data, reported an observed change in medication use during
73 the pandemic (5)(6). Changes in service delivery have been monitored through multiple
74 national audits which often lag considerably behind in real-time (7)(8). There is an urgent need
75 to focus appropriate resources on optimisation of medication dispensing monitoring systems,
76 especially in vulnerable patient groups; for example those receiving immunosuppressive drugs
77 (9).

78 Electronic dispensing records holding information on all dispensed prescriptions in primary
79 care, provide a unique opportunity to monitor dispensing trends. We aimed: 1) to measure the
80 general impact of COVID-19 on dispensing patterns; 2) create a national research ready dataset
81 of all primary care dispensing records for the whole population of Wales and 3) to design and
82 implement a tool for monitoring and visualisation real-time trends.

83 **Method**

84 **Study design and data sources**

85 We conducted a retrospective observational study, accessing national patient-level primary
86 care dispensing data using the SAIL Databank (10)(11). SAIL holds the Welsh Dispensing
87 DataSet (WDDS), which records information on all national health service (NHS) prescription

88 items dispensed by primary care dispensing contractors (community pharmacies, dispensing
89 general practices, general practices that personally administer prescription medication and
90 dispensing appliance contractors) from 2016, available on a monthly basis currently to end of
91 September 2020. (12)

92 The WDDS data is provided to the SAIL Databank by NHS Wales Shared Services Partnership
93 (NWSSP). The data is captured from prescriptions submitted to NWSSP, on a monthly basis,
94 by all primary care dispensing contractors to claim remuneration for dispensing in accordance
95 with the provisions of the National Health Service (Pharmaceutical and Local Pharmaceutical
96 Services) Regulations 2013. The WDDS dataset is limited to NHS prescriptions containing a
97 2D matrix barcode i.e. those that are produced by clinical systems in GP practices in Wales. It
98 therefore covers 94% of prescriptions dispensed and subsequently submitted for
99 reimbursement. Medications for Welsh residents that are dispensed against non-barcoded
100 prescriptions or dispensed outside Wales are not included in this dataset. These data are made
101 available to SAIL on a monthly basis with approximately a 6-week lag to allow for official
102 reporting and quality assurance processes (13).

103 Dispensing data from 1st of January 2016 to 31st of December 2019 (counterfactual pre-
104 COVID-19, “C16 cohort”) were compared to data from 1st January 2020 to the 31st of
105 September 2020 (COVID-19 year, “C20 cohort”). For all people who were alive and resident
106 in Wales with a record in the two purpose-built residency spine datasets (13), drug dispensing
107 history was retrieved from patient-level linked dispensing record using anonymized linkage
108 fields, and the date of dispensing of the drugs.

109 Dispensed items in WDDS are originally coded in Dictionary of Medicines and Devices
110 (DM+D), which we mapped at a per code level to their corresponding British National
111 Formulary (BNF) code(s) using an extract of mappings from National Health Service Business

112 Services Authority (NHS-BSA) services published on December 2020 (14). Where the BSA
113 mapping is not defined, NHS Terminology Reference-Data Update Distribution (known as
114 TRUD) tables were used to map DM+D codes to 7th character BNF codes (15) (see
115 Supplementary 1 for more details on mapping).

116 Data were aggregated by month and year, for items in each British National Formulary (BNF)
117 chapter. We compared dispensing rates between the C16 and C20 cohorts for the three main
118 BNF chapters: I) Cardiovascular Systems, II) Central Nervous System and III) Immunological
119 Products & Vaccines. We calculated age-standardised dispensing rates per 100,000 population.
120 Five-year age bands were used with upper bound of all those aging 90 years or more using the
121 2013 European Standard Population (ESP) (16). Dispensing trends were assessed based on
122 total quantity of dispensed items for each BNF chapter (17) per year and the number of patients
123 who have had at least one item dispensed, as documented in their WDDS records.

124 **Statistical analysis**

125 Per person dispensing rates were calculated based on the total number of dispensed items and
126 total number of patients with a dispensing record on each period. Dispensing rates were
127 calculated for 2020 and the counterfactual period of 2016 to 2019. The difference (D) and
128 relative changes (RC) were calculated for comparison of monthly trends in dispensing between
129 2020 records and 2019. All statistical procedures are performed in R (v3.5) and the codes are
130 available at <https://github.com/SwanseaUniversityMedical/WDDS>.

131 **Interactive tool**

132 We developed an interactive tool using R shiny (18) which allows dynamic monitoring of
133 trends in the current year and enables comparison between the most up to date data with
134 previous years' patterns. The dashboard is accessible from <https://wdds.ml/>.

135 **Results**

136 **Cohort curation**

137 3,139,662 patients with a total of 353,516,236 dispensing records entered in the WDDS were
138 linked in two COVID-19 e-cohorts (13). This comprised 87.7% of Welsh residents between
139 2016 and 2019 (C16) who had at least one dispensing record in WDDS and could be
140 successfully linked. The percentage for those with residency record at the start of 2020 (C20)
141 was 93.5%. A mapping rate of 99.7% was achieved for mapping all dispensed records from
142 DM+D to BNF codes for individuals in both the C16 and C20 cohorts who had linked data
143 available for analysis (Figure 1 & Supplementary 1).

144 **Drug dispensing trends**

145 There was a 5.25% increase in total dispensed items in 2020 compared to the previous year
146 (52,357,639 vs 49,747,141; 95% CI [5.21, 5.29]); while, overall rate of dispensed items per
147 person remained unchanged: 26.25 items were dispensed per individual in 2019 and 25.92 in
148 2020 representing an Difference (D) of -0.3 and a Relative Change (RC) of -0.01% (Table 1.a).
149 Comparison of monthly patterns of dispensed items between 2020 and 2019 showed an a
150 notable difference between the total number of dispensed drug items each month, with an
151 average difference of 290,055 and average RC of 5.52%. In the first two months of 2020, total
152 number of dispensed items were 6% higher than 2019 (average D = +318,939, average RC =
153 +6%). In March 2020, the total number of dispensed items was 28% higher than 2019 (D=
154 +1,501,242, RC= +28.05%). Fewer items were dispensed in April 2020 than April 2019 (D= -
155 23,767, RC= -0.42%) and a further negative fall was observed in May 2020, where the total
156 number of dispensed items was 5.88% lower than in May 2019 (D= -339,244, RC= -5.88). A
157 second peak in total number of monthly dispensed items was observed in June of 2020 (D=
158 +565,004, RC= +10.97%). Although the number of dispensed items increased in June, this was

159 followed by a further reduction of total numbers in subsequent months with an average of
160 2.69% lower dispensing in July and August of 2020 compared to the same periods in 2019
161 (average D= -153,795, average RC= -2.69). A third peak representing a 9.7% greater number
162 of dispensed items was observed in September 2020 compared to September 2019 (D=
163 +529,442, RC= +9.75%) (Table 1.b).

164 Overall, comparison of relative changes in dispensing for 2020 vs 2019, between the first peak
165 in dispensing in March (RC=+28.05%), the second peak in June (RC=+10.97%) and third peak
166 in September (RC=+9.75%) indicates a progressive return towards pre-COVID-19 monthly
167 dispensing patterns.

168 The observed increase in in March was consistent for items in the majority of BNF chapters,
169 except for items in the *Anaesthesia* and the *Immunological products & Vaccines* and *Dressings*
170 chapters, where the dispensing patterns were different to the overall patterns (Figure 2. For
171 dynamic comparisons of all years, please see Supplementary Figures 2.1 & 2.2 or visit out
172 online dashboard at <http://wdds.ml/>).


173 **Trends of drug dispensing rates in three selected major BNF sections over years**

174 Using age standardised dispensing rates, we focused on the comparison between 2019 and 2020
175 for Cardiovascular Systems (CVS), Central Nervous Systems (CNS) and Immunological
176 Products and Vaccines (IPV). All three groups showed similar trends between the years for
177 January and February. For CVS, dispensing increased considerably during March, however for
178 subsequent months there was generally reduced dispensing, until recovery to 2019 levels in
179 September (Figure 3 – Supplementary Figure 3.1). For CNS, the March 2020 peak was again
180 observed, however only May appeared to show significant reductions compared to 2019
181 (Figure 4 – Supplementary Figure 3.2). The notable outlier was IPV. Although the 2020

182 dispensing patterns for January and February mirrored 2019 level, for all other months (and
183 across all age groups) there was a large decline (Figure 5 – Supplementary Figure 3.3).

184

185 Figure 1: CONSORT of cohort extraction and number of matched mapped DM+D codes to BNF



186

187 *Table 1-a: number of dispensed items per year*

Year	Number of dispensed items (up to end of Sep)	Number of patients with a dispensed record (up to end of Sep)	Dispensed Rate per person	Number of dispensed items (Full year*)	Number of patients with a dispensed record (Full year)	Dispensed Rate per person
2020	52,357,639	2,020,298	25.92	69,810,185	2,057,953	33.92
2019	49,747,141	1,895,365	26.25	66,539,725	1,998,607	33.29
2018	48,798,853	1,940,080	25.15	65,591,106	2,042,733	32.11
2017	46,554,918	1,978,408	23.53	62,522,297	2,090,082	29.91
2016	45,501,194	2,045,059	22.25	60,739,546	2,155,068	28.18


*Presented numbers include estimate counts for 3 remaining months(Oct, Nov and Dec) of 2020

188 *Table 1.b: number of dispensed items per month of the year*


Month	Number of dispensed items 2020	Number of dispensed items 2019	Difference (D)*	Relative Change% (RC)*
Jan	6,108,259	5,776,287	331,972	5.75
Feb	5,417,522	5,111,617	305,905	5.98
Mar	6,853,990	5,352,748	1,501,242	28.05
Apr	5,747,006	5,723,239	23,767	0.42
May	5,427,000	5,766,244	-339,244	-5.88
Jun	5,717,634	5,152,630	565,004	10.97
Jul	5,825,965	5,986,661	-160,696	-2.68
Aug	5,299,653	5,446,546	-146,893	-2.7
Sep	5,960,611	5,431,169	529,442	9.75

*Signs indicate direction of change in 2020 compared to 2019

Figure 2- Number of dispensed items per BNF chapter per month – in 2020 vs 2019 (numbers of each chapter are individually scaled)




191 *Figure 3- Age-standardized dispensing rates for cardiovascular system in per 100,000 pop'n per year and month for 2020 vs 2019*




192

193 *Figure 4- Age-standardized dispensing rates for Central Nervous System in per 100,000 pop'n per year and month for 2020 vs 2019*



194

195 *Figure 5- Age-standardized dispensing rates for **Immunological Products & Vaccines** in per 100,000 pop'n per year and month for 2020 vs 2019*



196

197 **Discussion**

198 **Summary of findings**

199 This rapid assimilation of national dispensing data in Wales resulted in construction and
200 curation of a research ready linked dataset. Our data have shown in detail, over all BNF
201 chapters, changes in patterns of drugs dispensed during COVID-19 period. In general, the peak
202 in total numbers of dispensed items coincided with the first UK national lockdown, at the first
203 peak of the epidemic in March 2020. Our web application tool was developed for this
204 comparative analysis using aggregated level data to enable timely monitoring of dispensing
205 trends over time as the care system adapts to the evolving challenges of the pandemic.

206 We observed a dramatic reduction in the dispensing of Immunological Products & Vaccines at
207 the start of lockdown in COVID-19 period. While routinely dispensed vaccines in pharmacies
208 are mainly related to travel - such as yellow fever and rabies, the demand for these have
209 naturally been reduced during the COVID-19 period. Similarly, obtaining vaccines from
210 pharmacies through practice nurses prior to house visits may have been less frequent during
211 COVID-19 lockdown periods. The current COVID-19 pandemic has perturbed routine
212 immunisation and has led to dramatic shifts in the dispensing of Immunological Products &
213 Vaccines (19)(20).

214 While our observation matches to what has been reported in other studies such as Kaye et al.
215 (5); the increase of dispensed items in March cannot solely be considered as a better adherence.
216 Our data showed that this peak occurred in most drug categories and was followed by a dip in
217 the following two months (lockdown period) which is suggestive of batch-dispensing in
218 preparation of the national lockdowns. It is also likely that patients may have had spare
219 prescriptions to hand and felt an urgent to get them dispensed.

220 **Strengths and limitations**

221 The patient level data used in our study are available as a monthly extract to SAIL Databank
222 at the patient level; this provides the opportunity to use aggregated level data for monitoring
223 trends in near real-time, as well as exploring the effect of patient-level factors such as age, sex,
224 socioeconomic status and ethnicity. This mechanism provides the powerful opportunity to
225 using these data not only to monitor and evaluate prescribing and dispensing trends in near
226 real-time, but also to explore the effect of changing treatment patterns on outcomes considering
227 a comprehensive selection of patient-level factors. Our study developed a version of the linked
228 dispensing data which has mapped DM+D codes to the BNF codes and chapters. This
229 provides an opportunity to further investigate trends within each drug category, as well as wider
230 collaboration across harmonised data sources.

231 **Conclusion**

232 Dispensing patterns can be used as a proxy measure for monitoring community and population
233 level effects of COVID-19 on healthcare services. By providing a unique and transparent
234 system for continuous monitoring of drug prescribing and dispensing, this approach offers an
235 unprecedented opportunity to evaluate the clinical and health economic impacts of changes in
236 treatment patterns, potentially identifying areas in need of quality improvement programmes
237 as well as novel insights into disease management.

238 **Declarations**

239

240 **Ethics approval and consent to participate**

241 The data used in this study are available in the SAIL Databank at Swansea University, Swansea,
242 UK. All proposals to use SAIL data are subject to review by an independent Information
243 Governance Review Panel (IGRP). Before any data can be accessed, approval must be given
244 by the IGRP. The IGRP gives careful consideration to each project to ensure proper and

245 appropriate use of SAIL data. When access has been approved, it is gained through a privacy-
246 protecting safe haven and remote access system referred to as the SAIL Gateway. SAIL has
247 established an application process to be followed by anyone who would like to access data via
248 SAIL <https://www.saildatabank.com/application-process>. This study has been approved by
249 SAIL Information Governance Review Panel (IGRP) under application/project number 0911
250 and all research conducted in this study has been completed under the permission and approval
251 of the IGRP.

252

253 **Availability of data and materials**

254 The aggregated results data used in this study is available for download from our website:

255 <https://wdds.ml/> with other materials such as code being accessible from repository at:

256 <https://github.com/SwanseaUniversityMedical/concept-library>

257 The main patient-level data sources used in this study are available in the SAIL Databank at
258 Swansea University, Swansea, UK, but as restrictions apply they are not publicly available. All
259 proposals to use SAIL data are subject to review by an independent Information Governance
260 Review Panel (IGRP). Before any data can be accessed, approval must be given by the IGRP.

261 The IGRP gives careful consideration to each project to ensure proper and appropriate use of
262 SAIL data. When access has been granted, it is gained through a privacy protecting safe haven
263 and remote access system referred to as the SAIL Gateway. SAIL has established an application
264 process to be followed by anyone who would like to access data via SAIL at
265 <https://www.saildatabank.com/application-process/>

266 **Competing interests**

267 The author(s) declare(s) that they have no competing interests.

268 **Funding**

269 This work was supported by the Medical Research Council [MR/V028367/1]; Health Data
270 Research UK [HDR-9006] which receives its funding from the UK Medical Research Council,
271 Engineering and Physical Sciences Research Council, Economic and Social Research Council,
272 Department of Health and Social Care (England), Chief Scientist Office of the Scottish
273 Government Health and Social Care Directorates, Health and Social Care Research and
274 Development Division (Welsh Government), Public Health Agency (Northern Ireland), British
275 Heart Foundation (BHF) and the Wellcome Trust; and Administrative Data Research UK
276 which is funded by the Economic and Social Research Council [grant ES/S007393/1].

277

278 **Authors' contributions**

279 FT and AA contributed to all of the steps of the design, implementation, analysis and writing
280 of the manuscript from inception. AA developed the proposal and the main conceptual idea.
281 AA and LN contributed to development of mapping algorithm. FT and AA contributed to
282 finalisation of mapping algorithm and analysis. FT designed, implemented and deployed the
283 online tool. FT and AA jointly developed the first draft of the manuscript. RA, MG, JH and
284 DH conceived and designed the analysis. All authors have discussed, reviewed and contributed
285 to the final manuscript.

286

287

288 **Acknowledgements**

289 This work uses data provided by patients and collected by the NHS as part of their care and
290 support. We would also like to acknowledge all data providers who make anonymised data
291 available for research.

292 We wish to acknowledge the collaborative partnership that enabled acquisition and access to
293 the de-identified data, which led to this output. The collaboration was led by the Swansea
294 University Health Data Research UK team under the direction of the Welsh Government
295 Technical Advisory Cell (TAC) and includes the following groups and organisations: the
296 Secure Anonymised Information Linkage (SAIL) Databank, Administrative Data Research
297 (ADR) Wales, NHS Wales Informatics Service (NWIS), Public Health Wales, NHS Shared
298 Services Partnership and the Welsh Ambulance Service Trust (WAST). All research conducted
299 has been completed under the permission and approval of the SAIL independent Information
300 Governance Review Panel (IGRP) project number 0911.

301 **Public and patient involvement**

302 This project is undertaken under a proposal which has been submitted to the independent
303 Information Governance Review Panel (IGRP) that includes members of the public (IGRP
304 Project: 0911). Two members of the public are contributing to the scientific steering group of
305 IGRP panel. Although the need for fast track analysis of these data in response to COVID-19
306 redirected our main focus to the research and the nature of anonymised patient data isolates the
307 researcher from direct contact with patients involved in the study; however, the development
308 of our online visualisation tool was intended for a lay audience. We are also intending to work
309 closely with SAIL consumer panel group who are facilitating patient and public engagement
310 through providing a platform for research to be presented and reviewed by members of public.

311 **References**

312 1. Armitage R, Nellums LB. Antibiotic prescribing in general practice during COVID-19

- 313 [Internet]. Vol. 0, The Lancet Infectious Diseases. Lancet Publishing Group; 2020
314 [cited 2021 Feb 4]. Available from: <https://doi.org/10.1016/S1473-3099>
- 315 2. Pettus K, Cleary JF, de Lima L, Ahmed E, Radbruch L. Availability of Internationally
316 Controlled Essential Medicines in the COVID-19 Pandemic. *J Pain Symptom Manage*
317 [Internet]. 2020 Aug 1 [cited 2021 Feb 4];60(2):e48–51. Available from:
318 <https://pubmed.ncbi.nlm.nih.gov/32387575/>
- 319 3. Wright JH, Caudill R. Remote treatment delivery in response to the COVID-19
320 Pandemic [Internet]. Vol. 89, *Psychotherapy and Psychosomatics*. S. Karger AG; 2020
321 [cited 2020 Nov 7]. p. 130–2. Available from:
322 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179517/>
- 323 4. Ayati N, Saiyarsarai P, Nikfar S. Short and long term impacts of COVID-19 on the
324 pharmaceutical sector. *DARU, J Pharm Sci* [Internet]. 2020 Jul 3 [cited 2020 Nov
325 7];1–7. Available from: <https://doi.org/10.1007/s40199-020-00358-5>
- 326 5. Kaye L, Theye B, Smeenk I, Gondalia R, Barrett MA, Stempel DA. Changes in
327 medication adherence among patients with asthma and COPD during the COVID-19
328 pandemic. *J Allergy Clin Immunol Pract*. 2020 Jul 1;8(7):2384–5.
- 329 6. Gul ZB, Atakli HD. Effect of the COVID-19 pandemic on drug compliance and
330 stigmatization in patients with epilepsy. *Epilepsy Behav* [Internet]. 2021 Jan 1 [cited
331 2021 Feb 3];114:107610. Available from: [/pmc/articles/PMC7685058/?report=abstract](https://pubmed.ncbi.nlm.nih.gov/pmc/articles/PMC7685058/?report=abstract)
- 332 7. Khan T, Alderson S, Francis JJ, Lorencatto F, Grant-Casey J, Stanworth SJ, et al.
333 Repeated analyses of national clinical audit reports demonstrate improvements in
334 feedback methods. *Implement Sci Commun* [Internet]. 2020 Dec 25 [cited 2021 Feb
335 4];1(1):106. Available from:
336 [https://implementationsciencecomms.biomedcentral.com/articles/10.1186/s43058-020-](https://implementationsciencecomms.biomedcentral.com/articles/10.1186/s43058-020-00089-3)
337 [00089-3](https://implementationsciencecomms.biomedcentral.com/articles/10.1186/s43058-020-00089-3)
- 338 8. Gale CP, Weston C, Denaxas S, Cunningham D, De Belder MA, Gray HH, et al.
339 Engaging with the clinical data transparency initiative: A view from the National
340 Institute for Cardiovascular Outcomes Research (NICOR) [Internet]. Vol. 98, *Heart*.
341 *Heart*; 2012 [cited 2021 Feb 4]. p. 1040–3. Available from:
342 <https://pubmed.ncbi.nlm.nih.gov/22739635/>
- 343 9. Venerito V, Lopalco G, Iannone F. COVID-19, rheumatic diseases and
344 immunosuppressive drugs: an appeal for medication adherence [Internet]. Vol. 40,
345 *Rheumatology International*. Springer; 2020 [cited 2021 Feb 3]. p. 827–8. Available
346 from: <https://doi.org/10.1007/s00296-020-04566-9>
- 347 10. Ford D V., Jones KH, Verplancke JP, Lyons RA, John G, Brown G, et al. The SAIL
348 Databank: Building a national architecture for e-health research and evaluation. *BMC*
349 *Health Serv Res*. 2009;9.
- 350 11. Lyons RA, Jones KH, John G, Brooks CJ, Verplancke JP, Ford D V., et al. The SAIL
351 databank: Linking multiple health and social care datasets. *BMC Med Inform Decis*
352 *Mak*. 2009;9(1).
- 353 12. Gateway HI. Welsh Dispensing DataSet-WDDDS [Internet]. 2020 [cited 2003 Oct 20].
354 Available from: [https://web.www.healthdatagateway.org/dataset/50ef6443-ed4b-40f9-](https://web.www.healthdatagateway.org/dataset/50ef6443-ed4b-40f9-97fb-1cfd53be6579)
355 [97fb-1cfd53be6579](https://web.www.healthdatagateway.org/dataset/50ef6443-ed4b-40f9-97fb-1cfd53be6579)

- 356 13. Lyons J, Akbari A, Torabi F, Davies GI, North L, Griffiths R, et al. Understanding and
357 responding to COVID-19 in Wales: protocol for a privacy-protecting data platform for
358 enhanced epidemiology and evaluation of interventions. *BMJ Open* [Internet]. 2020
359 Oct 21 [cited 2020 Nov 7];10(10):e043010. Available from:
360 <https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2020-043010>
- 361 14. BSA N. BNF SNOMED mapping [Internet]. 2020. 2020. Available from:
362 [https://www.nhsbsa.nhs.uk/prescription-data/understanding-our-data/bnf-snomed-](https://www.nhsbsa.nhs.uk/prescription-data/understanding-our-data/bnf-snomed-mapping)
363 [mapping](https://www.nhsbsa.nhs.uk/prescription-data/understanding-our-data/bnf-snomed-mapping)
- 364 15. Digital N. TRUD [Internet]. [cited 2019 Oct 20]. Available from:
365 <https://isd.digital.nhs.uk/trud3/user/guest/group/0/home>
- 366 16. ONS-European Standard Population [Internet]. [cited 2019 Oct 20]. Available from:
367 [https://webarchive.nationalarchives.gov.uk/20160106020035/http://www.ons.gov.uk/o](https://webarchive.nationalarchives.gov.uk/20160106020035/http://www.ons.gov.uk/ons/guide-method/user-guidance/health-and-life-events/revised-european-standard-population-2013--2013-esp-/index.html)
368 [ns/guide-method/user-guidance/health-and-life-events/revised-european-standard-](https://webarchive.nationalarchives.gov.uk/20160106020035/http://www.ons.gov.uk/ons/guide-method/user-guidance/health-and-life-events/revised-european-standard-population-2013--2013-esp-/index.html)
369 [population-2013--2013-esp-/index.html](https://webarchive.nationalarchives.gov.uk/20160106020035/http://www.ons.gov.uk/ons/guide-method/user-guidance/health-and-life-events/revised-european-standard-population-2013--2013-esp-/index.html)
- 370 17. All BNF sections [Internet]. 2020. Available from: <https://openprescribing.net/bnf/>
- 371 18. Web Application Framework for R [R package shiny version 1.6.0]. 2021 Jan 25 [cited
372 2021 Feb 5]; Available from: <https://cran.r-project.org/package=shiny>

373

374

375

376


377

378


379

380 **Supplementary Figure 1**

381 *1. a: Mapping of DM+D codes from WDDS to BNF codes*




382



383

384

385 *1.b: Number of dispensed items for individuals residing in Wales and linked to WDDS*



386

387

388

389

390

391

392

393


394

395 **List of abbreviations**

Full term	Abbreviation
D	Difference
RC	Relative Change
WDDS	Welsh Dispensing DataSet
C16	Electronic cohort for period of 2016-2019 (3)
C20	Electronic cohort for 2020
WDDS	Welsh Dispensing DataSet
CVS	Cardiovascular Systems
CNS	Central Nervous Systems
IVP	Immunological Products and Vaccines
NHS TRUD	Terminology Reference-Data Update Distribution
NHS BSA	NHS Business Services Authority
TDI	Total Dispensed Items
DM+D	Dictionary of medicines and devices
BNF	British National Formulary
Pop'n	Population


396

397 Supplementary Figure 2.1- Number of dispensed items per BNF chapter-2020 vs 2019 harmonized scale




398

399 *Supplementary Figure 2.2- Number of dispensed items per BNF chapter per month –in all years (numbers of each chapter are individually*
 400 *scaled)*




401

402 *Supplementary Figure 2.3- Number of dispensed items per BNF chapter per month –in all years - harmonized scale*




403

404 *Supplementary Figure 3.1- Age-standardized dispensing rates for cardiovascular system in per 100,000 pop'n per year and month*



405

406 *Supplementary Figure 3.2- Age-standardized dispensing rates for Central Nervous System in per 100,000 pop'n per year and month*



407

